Advanced Solid Tumor Clinical Trials in San Antonio, Texas

43 studies are recruiting for advanced solid tumor in San Antonio, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies, page 2

1. A Study of PYX-201 in Advanced Solid Tumors

   The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with recurrent/metastatic (R/M) solid tumors, and to determine the objective response rate (ORR) in participants treated with PYX-201 as a single agent.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT San Antonio, San Antonio, Texas

   Locations

   29 in total

   Run by

   Pyxis Oncology, Inc

   See if you can join NCT05720117 on ClinicalTrials.gov

2. A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors

   This study consists of a Dose-Escalation stage and a Dose Expansion stage. The primary purpose of the dose escalation stage is to determine the maximum tolerated dose (MTD) and/or recommended dosage(s) for expansion (RDE[s]); and the dose expansion stage is to evaluate the preliminary antitumor act…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Exelixis Clinical Site #2, San Antonio, Texas

   Locations

   11 in total

   Run by

   Exelixis

   See if you can join NCT06952010 on ClinicalTrials.gov

3. A Study of YL201 in Patients With Advanced Solid Tumors

   This is a phase 1, multicenter, nonrandomized, open-label, first-in-human study of YL201 conducted in China and the United States. The study will include 2 parts: a dose escalation part (Part 1) followed by a dose expansion part (Part 2). Part 1 will estimate the MTD/RED(s) in dose escalation cohor…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   013, San Antonio, Texas

   Locations

   45 in total

   Run by

   MediLink Therapeutics (Suzhou) Co., Ltd.

   See if you can join NCT05434234 on ClinicalTrials.gov

4. A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

   This study investigates the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EIK1003 in participants with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 to 89

   Site

   START - South Texas Accelerated Research Therapeutics, San Antonio, Texas

   Locations

   57 in total

   Run by

   Eikon Therapeutics

   See if you can join NCT06253130 on ClinicalTrials.gov

5. First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

   A multicenter, single-arm, first-in-human study to investigate the safety, pharmacokinetics, and preliminary antitumor activity of PLX-61639 in participants with locally advanced or metastatic, relapsed/refractory, SMARCA4-deficient solid tumors who are intolerant of or have failed available, appro…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, San Antonio, Texas

   Locations

   10 in total

   Run by

   Plexium, Inc.

   See if you can join NCT07284186 on ClinicalTrials.gov

6. Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors

   This is a study that will enroll patients with cancer who have tumors that may have spread. The patients will know what medication they are being given. There will be 2 parts to the study. For the first part of the study only one medication will be taken, and the dose changed to a higher dose over …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Texas Health Science Center at San Antonio, San Antonio, Texas

   Run by

   Lei Zheng

   See if you can join NCT07086768 on ClinicalTrials.gov

7. Study in Advanced Solid Tumor Patients

   The study will be conducted in 2 phases: Phase 1: Dose-escalation and Dose Level Expansion, Phase 1 will determine the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE). Phase 2: Tumor-Specific Expansions with Dose Optimization, Phase 2 will further evaluate CLIO-8221 in tumo…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START San Antonio, San Antonio, Texas

   Locations

   11 in total

   Run by

   Callio Therapeutics

   See if you can join NCT07300943 on ClinicalTrials.gov

8. Evaluate the Safety and Clinical Activity of HH2853

   This is an open-label, multicenter, first-in-human phase I/II study which is composed of 3 parts: phase I dose escalation, phase I dose extension and phase II. HH2853 will be administered orally on a continuous BID schedule on a continuous 28-day treatment cycle.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology, San Antonio, Texas

   Locations

   25 in total

   Run by

   Haihe Biopharma Co., Ltd.

   See if you can join NCT04390737 on ClinicalTrials.gov

9. A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors

   This is a 3-part study. Phase 1a (dose escalation) is designed to assess the safety and tolerability and to determine the maximum tolerated dose (MTD) and putative recommended phase 2 dose (RP2D) of study drug as monotherapy. Phase 1b (Cohort Expansion) is intended to further characterize the safet…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology, San Antonio, Texas

   Locations

   6 in total

   Run by

   OBI Pharma, Inc

   See if you can join NCT07124117 on ClinicalTrials.gov

10. A Study of YL242 in Subjects With Advanced Solid Tumors

    This is a multicenter, open-label study to evaluate the safety and tolerability of YL242 monotherapy and combination in participants with advanced solid malignant tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    US-207, San Antonio, Texas

    Locations

    15 in total

    Run by

    MediLink Therapeutics (Suzhou) Co., Ltd.

    See if you can join NCT07197827 on ClinicalTrials.gov

11. Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment

    This is a phase 1, multi-center, open-label, dose-escalation study of nab-sirolimus in adult patients with locally advanced or metastatic solid tumors and moderate hepatic impairment or normal hepatic function.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas

    Locations

    2 in total

    Run by

    Aadi Bioscience, Inc.

    See if you can join NCT05661461 on ClinicalTrials.gov

12. Clinical Trial of PM54 in Advanced Solid Tumors Patients.

    The first part of the study (phase Ia - dose escalation) will evaluate the safety and tolerability and identify the dose-limiting toxicities (DLTs) of PM54. The second part of the study (phase Ib - safety run-in and expansion) will be to reassess the maximum tolerated dose (MTD) defined in the Phas…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    South Texas Accelerated Research Therapeutics, San Antonio, Texas

    Locations

    3 in total

    Run by

    PharmaMar

    See if you can join NCT05841563 on ClinicalTrials.gov

13. A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

    This is a first-in-human (FIH), multicenter, open-label Phase I study to investigate the safety, tolerability, preliminary antitumor activity, as well as pharmacokinetics (PK) and pharmacodynamics of XL309 (previously ISM3091) administered alone or in combination with olaparib in participants with …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Exelixis Clinical Site #3, San Antonio, Texas

    Locations

    16 in total

    Run by

    Exelixis

    See if you can join NCT05932862 on ClinicalTrials.gov

14. A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849

    This is the first-in-human, multicenter, open-label Phase I/II study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of FB849 alone and in combination with pembrolizumab in subjects with advanced solid tumors for whom no standard therapy is…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Oncology San Antonio, San Antonio, Texas

    Locations

    5 in total

    Run by

    1ST Biotherapeutics, Inc.

    See if you can join NCT05761223 on ClinicalTrials.gov

15. This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors

    This is a first-in-human Phase 1, single-arm, open-label, multicenter, multiple-dose, dose-escalation and dose-expansion study of ABL503 to evaluate the safety, tolerability, MTD and/or RP2D, PK, immunogenicity, preliminary antitumor activity, and the PD effect of ABL503 in subjects with any progre…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Oncology, San Antonio, Texas

    Locations

    8 in total

    Run by

    ABL Bio, Inc.

    See if you can join NCT04762641 on ClinicalTrials.gov

16. A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

    This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR502 administered as a monotherapy and in combination with cemiplimab in subje…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Oncology, San Antonio, Texas

    Locations

    4 in total

    Run by

    OncoResponse, Inc.

    See if you can join NCT06090266 on ClinicalTrials.gov

17. A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors

    It is a Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0036 in Subjects with Advanced Solid Tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Next Oncology, San Antonio, Texas

    Locations

    4 in total

    Run by

    Shanghai Huaota Biopharmaceutical Co., Ltd.

    See if you can join NCT05417321 on ClinicalTrials.gov

18. Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors

    This study consists of Part A for monotherapy and Part B for combination therapy to evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy of TU2218 in patients with advanced solid tumors. The main purpose of Phase 1 is to determined the recommended Phase 2 dose (RP2D) of TU2218 …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Oncology, San Antonio, Texas

    Locations

    3 in total

    Run by

    TiumBio Co., Ltd.

    See if you can join NCT05204862 on ClinicalTrials.gov